Background and Purpose-The purpose of this study was to investigate the frequency of symptomatic in-stent restenosis (ISR) and its contribution to nonprocedural symptomatic infarction in the SAMMPRIS trial (Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis). Methods-Patients without a periprocedural primary end point were followed up to determine the occurrence of any of the following events: ischemic stroke, cerebral infarct with temporary signs, or transient ischemic attack in the territory of the stented artery. Vascular imaging performed after these events was reviewed for ISR. Annual rates for symptomatic ISR were calculated using Kaplan-Meier estimates. Results-Of 183 patients in the stenting group without a periprocedural primary end point, 27 (14.8%) had a symptomatic infarction (stroke or cerebral infarct with temporary signs) and 16 (8.7%) had transient ischemic attack alone in the territory during a median follow-up of 35.0 months. Of the 27 patients with infarctions, 17 (9.3%) had an ischemic stroke and 10 (5.5%) had a cerebral infarct with temporary signs alone. ). The 1-, 2-, and 3-year rates (with 95% confidence limits) for symptomatic ISR in the SAMMPRIS stent cohort were 9.6% (6.1%-14.9%), 11.3% (7.5%-17.0%), and 14.0% (9.6%-20.2%), respectively. Conclusions-Symptomatic ISR occurred in at least 1 of 7 patients in SAMMPRIS by 3 years of follow-up and was likely responsible for the majority of nonprocedural cerebral infarctions. Clinical Trial Registration-URL: https://clinicaltrials.gov. Unique identifier: NCT00576693.
nrollment in the SAMMPRIS trial (Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis) was stopped early because of a higher rate of 30-day stroke and death in the stenting arm relative to aggressive medical management. 1 Aggressive medical management and follow-up continued, and long-term follow-up (mean, 32.4 months) showed no late gain for the percutaneous transluminal angioplasty and stent (PTAS) arm: stroke rates after 30-day procedural events were similar between medical and interventional arms. 2 Beyond 30 days, 21 of 210 patients (10%) in the medical group and 19 of 191 patients (10%) in the PTAS group had a primary end point. 2 One factor that may have been responsible for many of the nonprocedural strokes after intracranial PTAS for intracranial atherosclerotic disease is in-stent restenosis (ISR). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Although previous studies have described the incidence of ISR after PTAS for intracranial atherosclerotic disease, with or without the Wingspan stent, most of these studies include both symptomatic and asymptomatic ISR. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] We undertook this analysis to estimate the rate of symptomatic ISR in SAMMPRIS.
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Methods
SAMMPRIS was a randomized, multicenter clinical trial. 1, 2, 16 The study design has been published. 1, 16 Eligibility criteria included either transient ischemic attack (TIA) or nondisabling stroke within 30 days before enrollment attributable to angiographically verified 70% to 99% stenosis of a major intracranial artery. Enrollment in the trial began in November 2008 and was stopped in April 2011. Medical treatment and follow-up of enrolled patients were completed in April 2013. The SAMMPRIS study was approved by local institutional review boards at each site.
This study is a post hoc analysis of the data collected in the trial. Patients assigned to the PTAS arm who had successful (no periprocedural complications) PTAS or angioplasty alone and any of the following events >30 days after enrollment were identified: (1) an ischemic stroke in the territory of the target artery, (2) cerebral infarction with transient signs (CITS) in the territory, or (3) TIA in the territory. Ischemic stroke in the territory of the qualifying artery was a primary end point and was defined as a new focal neurological deficit of sudden onset, lasting at least 24 hours that was not associated with a hemorrhage on brain imaging. A CITS, which was considered a subtype of TIA and not a primary end point in SAMMPRIS, was defined as a new focal neurological deficit of sudden onset that lasted for <24 hours but was associated with a new infarct on brain imaging. TIA was defined as a new focal neurological deficit of sudden onset that lasted for <24 hours and was not associated with a new infarct on brain imaging if performed. Subjects were not followed up for recurrent events after a primary end point but were for CITS and TIA. Details about any repeat revascularization procedures of the target artery performed before a primary end point were collected. Study records, including case report forms, procedure and progress notes, discharge or death summaries, electronically archived imaging, and records of central end point adjudication on all patients with any of the events described above, were reviewed.
PTAS Procedure
The Gateway PTA Balloon Catheter and Wingspan Stent System (Boston Scientific Corporation, Stryker Neurovascular, Fremont, CA) wascused for PTAS in the trial. Specific aspects of the study protocol for PTAS procedure, post-procedure care, and aggressive medical management have been published. 1, 17 A 600-mg loading dose between 6 and 24 hours before PTAS was required if the patient was not on daily clopidogrel (75 mg) for 5 days before PTAS.
Central Adjudication of Nonprocedural Primary End Points in the PTAS Group
Detailed analyses of the 30-day outcomes of the stented patients in SAMMPRIS have been reported previously. [18] [19] [20] Beyond 30 days, clinical evaluations of treated patients were required at 4-month intervals to a common termination date 2 years after enrollment of the last patient. Patients with a suspected stroke were examined by a study neurologist, and any brain imaging was reviewed. Vascular imaging was obtained at the discretion of the investigators or treating physicians. All ischemic strokes (ie, neurological signs lasting >24 hours) and TIAs lasting >1 hour were reported by sites and centrally adjudicated. TIAs associated with an infarct were classified as CITS. For the present investigation, all reported TIAs were reviewed blinded to treatment assignment by 2 study investigators to determine whether they met the definition of a CITS or TIA in the territory.
In-Stent Restenosis
All available vascular imaging (computed tomographic angiography [CTA] , magnetic resonance angiography [MRA] , and digital subtraction angiography [DSA] ) for all patients who had a primary end point, CITS, or TIA in the territory beyond 30 days of enrollment was reviewed by 2 investigators. If patients had a CTA or MRA followed by DSA, the DSA study was used to determine ISR. ISR was defined as >50% stenosis within or immediately adjacent (within 5 mm) of the implanted stent and >20% absolute luminal loss. 3 This was scored as definite, probable, absent (≤50% stenosis), or indeterminate (unable to evaluate because of the quality of the study or vascular imaging unavailable). Disagreements were resolved by consensus. Symptomatic ISR was defined as probable or definite ISR associated with ischemic symptoms in the territory.
Data Analysis
The analysis included patients who underwent angioplasty alone or PTAS who did not have a primary end point during the first 30 days after enrollment in the study. The Kaplan-Meier method was used to estimate the cumulative probability of symptomatic ISR versus time after enrollment. A patient having an adjudicated ischemic event in the territory associated with ISR was deemed to have had an end point at the time of the first such event. A patient not having an adjudicated ischemic event with ISR was censored at the time of a primary end point or the last study visit. In addition, patients having ≥1 adjudicated ischemic events whose ISR status could not be evaluated were censored at the first such event. Patients who were lost or who withdrew were censored at the last study visit completed. Analyses were done using SAS 9.3.
Results

Study Patients and Follow-Up
Of 224 patients in the stent arm, 4 patients declined the procedure after randomization, and in 7 patients, the procedure was aborted before the lesion was accessed (3 of whom had a periprocedural stroke). An additional 30 patients had a primary end point within 30 days after enrollment. The remaining 183 patients underwent a procedure (4 of whom had angioplasty only) and form the basis for the present analysis. Median follow-up of the 183 patients was 35.0 months (interquartile range, 27.8-42.3 months). Nine patients were either lost to follow-up or withdrew consent beyond 30 days after enrollment (3 within the first year and 6 after 2 years of follow-up).
Ischemic Events Beyond Periprocedural Period
Of the 183 patients in this study, 17 (9.3%) had an ischemic stroke in the territory during follow-up. The age, sex, symptomatic artery, timing of symptom onset, disability, and imaging findings for these 17 patients are listed in Table 1 . Two of the 17 patients had TIAs or CITS preceding a stroke (patients 6 and 15 in Table 1 ). The 15 remaining patients with ischemic stroke did not have a CITS or TIA in the territory before the ischemic stroke. For patients not having an ischemic stroke in the territory, the first occurring ischemic event in the territory after the 30-day periprocedural period was CITS in 10 patients (5.5% of the 183 patients) and TIA in 16 patients (8.7% of the 183 patients). The age, sex, symptomatic artery, timing of symptom onset, and ISR status/imaging modality for these 26 patients are listed in Table 2 . In total, of the 183 patients, 27 patients (14.8%) had a symptomatic infarction (17 ischemic strokes and 10 CITS alone) in the territory after the 30-day periprocedural period.
Frequency and Location of Symptomatic ISR
Of the 27 patients with a cerebral infarct in the territory beyond 30 days, vascular imaging to assess for ISR was adequate in 24 patients, indeterminate in 1 patient, and missing in 2 patients. In the 24 patients with adequate imaging, definite or probable ISR was present in 16 (66.7%) and no ISR was seen in 8 (33.3%; Tables 1 and 2) . Two ischemic stroke patients assessed as having ISR presented with stent occlusion (patients 1 and 15 in Table 1 ). In the first, the proximal internal carotid was occluded, with flow through a narrowed channel in the distal aspect of the stent from an ophthalmic artery collateral. In the second, the patient presented with acute basilar thrombosis and severe ISR was identified during a thrombectomy procedure. Of the 17 patients with ischemic stroke after 30 days (Table 1) , 11 underwent DSA, 4 had CTA only, 1 had MRA only, and 1 had no imaging. Of the 10 patients with CITS after 30 days (Table 2) , 6 underwent DSA, 2 had CTA only, 1 had MRA only, and 1 had no imaging.
Of the 16 patients with a TIA alone in the territory beyond 30 days, vascular imaging to assess for ISR was adequate in 10 patients (7 with DSA, 2 with CTA, and 1 with MRA) and missing in 6. In the 10 patients with adequate imaging, definite or probable ISR was present in 8 (80%), and no ISR was seen in 2 (20%; Table 2 ). Excluding the 9 patients with indeterminate or missing vascular studies yielded an overall symptomatic ISR frequency of 24 of 174 (13.8%) patients in this study. The median time to symptomatic ISR among these 24 patients was 6.0 months (interquartile range, 3.8-16.1 months; range, 1.4-28.2 months). The 1-, 2-, and 3-year Kaplan-Meier rates (with 95% confidence limits) for symptomatic ISR among all 183 patients followed up beyond 30 days in the stenting arm were 9.6% (6.1%-14.9%), 11.3% (7.5%-17.0%), and 14.0% (9.6%-20.2%), respectively (Figure) .
Of the 174 patients who either had no ischemic events reported during follow-up (n=140) or had ischemic events for which an adequate vascular imaging study was performed (n=34), the frequencies of symptomatic ISR according to the treated artery were 10 of 77 (13.0%) for the middle cerebral artery, 6 of 31 (19.4%) for the internal carotid artery, 7 (18.4%) of 38 for the basilar artery, and 1 (3.6%) of 28 for the vertebral artery.
Subsequent Events in Patients With TIA and CITS Associated With ISR
The mean follow-up after the first ischemic event for the 28 patients with CITS or TIA (patient 2 in Table 1 who had TIA or CITS preceding a stroke and patient 26 in Table 2 ) was 24.9 months (SD, 10.2 months; range, 4.2-45.5 months). Of these 28 patients, 14 had ISR, 6 did not have ISR, and ISR was indeterminate in 8 at the time of their first ischemic event. Treatment after the first ischemic event in 14 patients Two other patients in SAMMPRIS had primary end points beyond 30 days after enrollment. One did not have angioplasty or stenting (procedure was aborted) and had a subsequent ischemic stroke and another had a symptomatic brain hemorrhage after repeat angioplasties for asymptomatic ISR. CTA indicates computed tomographic angiography; DSA, digital subtraction angiography; ISR, in-stent restenosis; MCA, middle cerebral artery; MRA, magnetic resonance angiography; SAMMPRIS, Stenting and Aggressive Medical Management for the Prevention of Recurrent Stroke in Intracranial Stenosis; and TIA, transient ischemic attack.
*For the definition of disabling stroke, see Table 3 in the article by Chimowitz et al.
1 †Patient 6 had several TIAs in the territory associated with ISR (the first 1 at 1.6 months after enrollment) leading to dual antiplatelet therapy and repeat angioplasties. The ischemic stroke occurred 3 days after an attempted repeat angioplasty that was aborted. ‡Patient 15 had a cerebral infarct with temporary signs in the territory 3.4 months after enrollment unrelated to ISR and was placed on dual antiplatelet therapy.
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with symptomatic ISR included dual antiplatelet therapy in 9 patients (patients 6 in Table 1 and 8 in Table 2 ) and aspirin alone in 5 patients (Table 2) . Of the 14 patients with symptomatic ISR, 2 underwent angioplasty (patient 6 in Table 1 and patient 25 in Table 2 ). One of the 2 underwent multiple repeat angioplasties and experienced an ischemic stroke (a primary end point) 3 days after an aborted attempt at repeat angioplasty. The second underwent repeat angioplasty for restenosis of a midbasilar lesion 18 months after enrollment and remained asymptomatic for the duration of subsequent follow-up (27 months). Of the remaining 12 patients with ISR, none had a subsequent ischemic stroke in the territory. Two had a CITS in the territory (patients 4 and 15 in Table 2 ). Four had recurrent TIAs in the territory (3 had single events and 1 had 3-patients 1, 11, 13, and 17 in Table 2 ).
Of the 14 patients with TIA or CITS who did not have ISR or in whom ISR was indeterminate, all were treated medically and 1 had a subsequent ischemic stroke in the territory (a primary end point). This was patient 15 in Table 2 , who had a CITS and no evidence of ISR 3.4 months after enrollment and then ischemic stroke at 28 months associated with ISR. One additional patient with a CITS at 3.5 months (patient 9, Table 2 ) had a recurrent TIA at 4 months and then remained asymptomatic for the remaining 27 months of follow-up. The remaining 12 patients had no further ischemic events in the territory for the duration of follow-up.
Discussion
SAMMPRIS provides unique data on the risk of symptomatic ISR after use of the Wingspan stent system. Symptomatic CITS indicates cerebral infarct with temporary signs; CTA, computed tomographic angiography; DAPT, dual antiplatelet; DSA, digital subtraction angiography; ISR, in-stent restenosis; MCA, middle cerebral artery; MRA, magnetic resonance angiography; and TIA, transient ischemic attack.
ISR was most frequent in the first year after PTAS and was associated with a majority of the cerebral infarcts and TIAs in the territory of the stented artery during follow-up. ISR is an important cause of nonprocedural ischemic events after intracranial stenting.
Most of the existing literature on the incidence of ISR includes both symptomatic and asymptomatic lesions. In the US Wingspan registry, Levy et al 3 reported a 29.7% overall rate of ISR (25 of 84 lesions in 68 patients) on follow-up vascular imaging obtained between 1.5 and 15.5 months after stenting. Eight of the 68 patients (12%) were symptomatic, 4 of whom had ISR and 4 had acute thrombosis. Fifteen of the 25 patients with ISR underwent repeat angioplasty. The symptomatic ISR rate of 12% is similar to the 13.8% symptomatic ISR in SAMMPRIS, but the length of follow-up was longer in SAMMPRIS. The definition of ISR used in the US Wingspan registry was identical to this study. 3 We cannot provide data on asymptomatic ISR rates in SAMMPRIS because follow-up vascular imaging was only allowed after the development of ischemic symptoms. This decision was made because the risk and benefit of angioplasty for asymptomatic ISR is unknown.
Asian studies have reported much lower rates of symptomatic ISR. Yu et al 4 reported ISR in 11 of 66 patients on routine angiographic follow-up at 1 year, none of which were symptomatic. Shin et al 5 reported ISR in 17 of 69 lesions (24.6%) at a median of 12 months, of which only 3 were symptomatic. The different rates of symptomatic ISR in SAMMPRIS and the Asian studies may be related to differences in study design. The Asian case series included routine surveillance for ISR with follow-up vascular imaging. Some patients with asymptomatic ISR underwent repeat angioplasty, with or without stenting. Others may have had changes in their antiplatelet regimen or other medications based on the results of the vascular imaging. Either of these interventions may have had an impact on reducing the rate of symptomatic ISR.
One pattern of ISR that was described in the US Wingspan Registry was progressive stenosis of the supraclinoid carotid. 15 ISR in this location was common, especially in younger patients, and was often recurrent. Turk et al 15 reported on a subset of 93 treated lesions that met study criteria for imaging surveillance out of a total of 144 patients with 155 treated lesions. They dichotomized the cohort by age >55 years and age ≤55 years and investigated subgroups by lesion location. ISR was more common in the younger patients (45% [14/31] versus 24% [15/62] , odds ratio, 2.6; 95% confidence interval, 1.0-6.5). Within the younger group, ISR was more common in anterior circulation (13 of 26 treated) than posterior circulation (1 of 5 treated). Five of the 14 younger patients with ISR were symptomatic. Eight of 9 lesions involving the supraclinoid segment developed ISR, with ischemic symptoms in 4 of the 8. The possibility of a nonatherosclerotic pathology underlying these lesions has been raised. 15 In the present analysis of SAMMPRIS data, 6 of 31 (19.4%) patients with intracranial carotid stenosis who were stented developed symptomatic ISR and only one of these underwent multiple repeat angioplasties for recurrent distal internal carotid artery/M1 segment ISR (patient 6 in Table 1 ). The low incidence of distal internal carotid artery/M1 segment symptomatic ISR observed in SAMMPRIS, relative to the Wingspan registry described above, may be related to the inclusion criteria in the SAMMPRIS trial that required patients aged <50 years to have at least 2 atherosclerotic risk factors to be enrolled.
The optimal management of patients with symptomatic ISR is unclear. This study provides unique data on the outcome of symptomatic ISR treated medically or with angioplasty. All 5 patients with CITS and ISR were treated medically only (4 with dual antiplatelet therapy) and all 5 patients remained stroke free during a median follow-up of 26.6 months although 1 had a TIA and another had a CITS (see CITS patients in Table 2 ). Two of the 9 patients with TIAs and ISR underwent angioplasty. The remaining 7 patients with TIA and ISR were treated medically (3 with dual antiplatelet therapy and 4 with aspirin). None had an ischemic stroke although 1 had a CITS and 3 had recurrent TIAs during follow-up (Table 2) . Although ISR accounted for a large number of ischemic events, including delayed stroke, in this cohort, the risk of a subsequent event on medical therapy seems to be low. These data suggest that the risk of subsequent ischemic events in most patients with symptomatic ISR may be time limited.
This post hoc study has some important limitations. ISR was diagnosed by DSA in the large majority of cases, but 1 was based on MRA that may overestimate the degree of stenosis. The rate of symptomatic ISR may be underestimated. It is possible that not all TIAs were reported by the sites. In addition, the 95% confidence intervals around the rates of symptomatic ISR are wide because of the sample size. Nevertheless, this is the largest prospective study of symptomatic ISR in patients undergoing stenting with the Wingspan stent in the United States. This study does not provide any data on the rate or clinical significance of asymptomatic ISR because routine vascular imaging was not part of the SAMMPRIS protocol. In addition, we have no data on the long-term outcome of patients after stroke associated with ISR because once patients were evaluated 90 days after the stroke, they were no longer followed in the trial.
In conclusion, symptomatic ISR occurred in at least 1 in 7 patients during a median follow-up of 35 months in SAMMPRIS and was associated with the majority of 
Stroke
symptomatic infarcts in the territory of the stented artery beyond the periprocedural period. Taken together with the periprocedural outcomes in SAMMPRIS, these data show that it will be necessary to substantially lower both the rate of periprocedural stroke and the rate of symptomatic ISR for stenting to have a role in the treatment of intracranial stenosis.
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